GENESIS Trial: Almost Ninety Percent of Multiple Myeloma Patients Were Able to Proceed to Transplantation

A recent article in Cancer Network announced that motixafortide met its primary endpoint in the GENESIS trial for multiple myeloma patients who were scheduled for stem cell transplantation. Often, the…

Continue Reading GENESIS Trial: Almost Ninety Percent of Multiple Myeloma Patients Were Able to Proceed to Transplantation
Impressive Results for Cilta-Cel to Treat Patients With Relapsed/Refractory Multiple Myeloma
qimono / Pixabay

Impressive Results for Cilta-Cel to Treat Patients With Relapsed/Refractory Multiple Myeloma

According to a recent report in Cancer Network, the results from CARTITUDE-1 were well received. CARTITUDE-1 is a phase 1b/2 clinical trial of the CAR T-cell treatment, Cilta-Cel, for the…

Continue Reading Impressive Results for Cilta-Cel to Treat Patients With Relapsed/Refractory Multiple Myeloma
Combining Three Drugs in the Treatment of Multiple Myeloma Patients Shows Solid Clinical Activity
source: pixabay.com

Combining Three Drugs in the Treatment of Multiple Myeloma Patients Shows Solid Clinical Activity

  According to data from the STOMP trial involving thirty-four patients, a triple regimen has been proven to induce durable responses in pretreated patients with relapsed/refractory multiple myeloma. A recent…

Continue Reading Combining Three Drugs in the Treatment of Multiple Myeloma Patients Shows Solid Clinical Activity
Genomic Markers Show the Risk of Progression for Smoldering Multiple Myeloma
mohamed_hassan / Pixabay

Genomic Markers Show the Risk of Progression for Smoldering Multiple Myeloma

According to the ASCO Post, researchers have discovered genomic characteristics of smoldering multiple myeloma that can tell one's risk of progression to multiple myeloma. Dr. Mark Bustoros and his team…

Continue Reading Genomic Markers Show the Risk of Progression for Smoldering Multiple Myeloma